Please login to the form below

melanoma

This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.

Lilly’s pegilodecakin fails in long-shot pancreatic cancer trial

Earlier-stage trials are ongoing in other advanced solid tumours including melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

Latest news

BMS plugs on with Opdivo plus Yervoy in first-line NSCLC

These results build upon the long-term clinical data in first-line melanoma and renal cell carcinoma demonstrating the benefit of combining Yervoy and Opdivo compared to standard of care," said
Boehringer bolsters KRAS push with $720m Lupin deal

MEK inhibitors are well established in oncology, but to date have been used mainly in combination with BRAF inhibitors in cancers such as melanoma.
Transgene slumps as viral cancer therapy fails phase 3 trial

It’s an approach that has already yielded one FDA- and EMA-approved product – Amgen’s Imlygic (talimogene laherparepvec) – which was launched in 2015 for melanoma but hasn’t made much
BioNTech raises €290m for mRNA cancer vaccine platform

Funds will help lead melanoma candidate progress. Germany’s BioNTech has raised a whopping 290m ($325m) in a second-round financing round that is one of the biggest ever completed by ... Bayer – says it will use a chunk of the proceeds to push its
Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

Sanofi and Regeneron aren’t holding back on the scale of their research programme, and these include trials in squamous cell carcinoma of the head and neck, melanoma, colorectal cancer, prostate

More from news
Approximately 79 fully matching, plus 278 partially matching documents found.

Latest Intelligence

Immuno-oncology in 2019: the rapid evolution continues

BMS led the charge when Opdivo became the first in its class to gain approval (in metastatic melanoma in December 2014 in Japan), but Merck &Co’s Keytruda has emerged as
Is China ready for a pharmaceutical gold rush?

China’s millions of tobacco smokers make for a large market, which may be why BMS filed for approval in lung cancer treatment, rather than melanoma, the leading indication in other
Combined immunotherapies – potential and pitfalls

The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.
Cancer immunotherapy: What's on the horizon?

had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.
Communication is the key to unlocking the potential of immuno-oncology

Decades later, in a twist of presidential fate, 92-year old fellow US President Jimmy Carter received his all clear from melanoma thanks in part to an entirely new way to

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

Industry appointments

Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
Packer Forbes appoints Jade McCudden

McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
Array appoints Victor Sandor chief medical officer

This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
Bruno Strigini leaves Merck & Co for Novartis

Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.
Chris Bowden joins Agios

During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

In its earlier phase 1 monotherapy trial, TAVO demonstrated a 46% response rate in untreated lesions in metastatic melanoma. ... Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to
Artificial Intelligence in Healthcare

It missed fewer melanomas, meaning it had a higher sensitivity, and it misdiagnosed fewer benign moles as malignant melanoma, meaning it also had a higher specificity.[15]. ... Man against machine: diagnostic performance of a deep learning convolutional
18 SWITCHED ONcology: The Big Communication

all clear from melanoma thanks to an entirely new way to treat The Big C.
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships

Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer